The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments

Lung cancer is a public health problem worldwide and Latin America (LATAM) cannot escape this reality. This malignant disease has not only a high prevalence in the region, but is also the main cause of cancer related deaths, and in other emerging countries, the incidence rates are still on the rise....

Full description

Autores:
Raez, Luis E.
Cardona-Mendoza, Andrés Felipe
Santos, Edgardo S.
Catoe, Heath
Rolfo, Christian
Lopes, Gilberto
Barrios, Carlos
Mas, Luis A.
Vallejos, Carlos
Zatarain-Barrón, Zyanya Lucia
Caglevic, Christian
Arrieta, Oscar
Tipo de recurso:
Article of journal
Fecha de publicación:
2018
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/3631
Acceso en línea:
http://hdl.handle.net/20.500.12495/3631
https://doi.org/10.1016/j.lungcan.2018.02.014
https://repositorio.unbosque.edu.co
Palabra clave:
Lung cancer
Latin America
Immunotherapy
Targeted therapy
Healthcare access
Rights
openAccess
License
Acceso abierto
id UNBOSQUE2_6ee4cfcf8d1de22e82408e60b83e9af2
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/3631
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
dc.title.translated.spa.fl_str_mv The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
title The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
spellingShingle The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
Lung cancer
Latin America
Immunotherapy
Targeted therapy
Healthcare access
title_short The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
title_full The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
title_fullStr The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
title_full_unstemmed The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
title_sort The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
dc.creator.fl_str_mv Raez, Luis E.
Cardona-Mendoza, Andrés Felipe
Santos, Edgardo S.
Catoe, Heath
Rolfo, Christian
Lopes, Gilberto
Barrios, Carlos
Mas, Luis A.
Vallejos, Carlos
Zatarain-Barrón, Zyanya Lucia
Caglevic, Christian
Arrieta, Oscar
dc.contributor.author.none.fl_str_mv Raez, Luis E.
Cardona-Mendoza, Andrés Felipe
Santos, Edgardo S.
Catoe, Heath
Rolfo, Christian
Lopes, Gilberto
Barrios, Carlos
Mas, Luis A.
Vallejos, Carlos
Zatarain-Barrón, Zyanya Lucia
Caglevic, Christian
Arrieta, Oscar
dc.contributor.orcid.none.fl_str_mv Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.subject.keywords.spa.fl_str_mv Lung cancer
Latin America
Immunotherapy
Targeted therapy
Healthcare access
topic Lung cancer
Latin America
Immunotherapy
Targeted therapy
Healthcare access
description Lung cancer is a public health problem worldwide and Latin America (LATAM) cannot escape this reality. This malignant disease has not only a high prevalence in the region, but is also the main cause of cancer related deaths, and in other emerging countries, the incidence rates are still on the rise. Interestingly in most LATAM countries, lung cancer mortality has been decreasing in men but not in women, reflecting smoking patterns in countries such as Chile, Bolivia, and Brazil. Despite the fact that these issues are well known to government agencies, physicians and patients in the region, current efforts still fall behind those needed in order to face this problem of epidemic proportions. Tobacco control and smoking cessation are the most important interventions against lung cancer, but even with their optimal implementation (which is far from reality at this time) the number of cases in the foreseeable future would still be significant. Beyond tobacco control, advances in our understanding of the molecular component of lung cancer have resulted in new targeted therapies and immune check point inhibitors, which have improved clinical outcomes but at a considerably higher financial cost. LATAM has not widely and speedily adopted these strategies, including new technology and approved novel drugs, due to a number of facts, and therefore only a dismal proportion of LATAḾs patient population have benefited from these new advances. A keen focus on a heterogeneous education system for caregivers in lung cancer treatment would likely help standardize care and improve future potential gains from domestic research. In this review we discuss the challenges of treatment implementation, focusing on new technologies.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018
dc.date.accessioned.none.fl_str_mv 2020-07-31T13:52:43Z
dc.date.available.none.fl_str_mv 2020-07-31T13:52:43Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 1872-8332
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/3631
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.lungcan.2018.02.014
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv https://repositorio.unbosque.edu.co
identifier_str_mv 1872-8332
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
url http://hdl.handle.net/20.500.12495/3631
https://doi.org/10.1016/j.lungcan.2018.02.014
https://repositorio.unbosque.edu.co
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Lung Cancer, 1872-8332, Vol. 119, 2018, p. 7-13
dc.relation.uri.none.fl_str_mv https://www.lungcancerjournal.info/article/S0169-5002(18)30271-X/abstract
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
dc.rights.creativecommons.none.fl_str_mv 2018-05
rights_invalid_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
2018-05
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.publisher.journal.spa.fl_str_mv Lung cancer
institution Universidad El Bosque
bitstream.url.fl_str_mv http://18.204.144.38/bitstreams/32d4e82d-357c-44ed-ad85-83205fc9ab68/download
http://18.204.144.38/bitstreams/34ced02b-a2e8-4b4a-8098-fb1633e4b461/download
http://18.204.144.38/bitstreams/2042d1a1-1ddb-4dd2-ae27-2bcf1b27de5c/download
http://18.204.144.38/bitstreams/a81a1a32-61ab-44bf-9c20-e6a2f22d6ecd/download
bitstream.checksum.fl_str_mv 3db98ea3ccf8ff15f31f727e9f67348d
8a4605be74aa9ea9d79846c1fba20a33
b70505959e6a479778e62b4a77bcf41c
f72e5479d74019bef6edc507541a2bb4
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv DSpace Pre-instalado Biteca S.A.S
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814100688935845888
spelling Raez, Luis E.Cardona-Mendoza, Andrés FelipeSantos, Edgardo S.Catoe, HeathRolfo, ChristianLopes, GilbertoBarrios, CarlosMas, Luis A.Vallejos, CarlosZatarain-Barrón, Zyanya LuciaCaglevic, ChristianArrieta, OscarCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]2020-07-31T13:52:43Z2020-07-31T13:52:43Z20181872-8332http://hdl.handle.net/20.500.12495/3631https://doi.org/10.1016/j.lungcan.2018.02.014instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coapplication/pdfengElsevierLung cancerLung Cancer, 1872-8332, Vol. 119, 2018, p. 7-13https://www.lungcancerjournal.info/article/S0169-5002(18)30271-X/abstractThe burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsThe burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Lung cancerLatin AmericaImmunotherapyTargeted therapyHealthcare accessLung cancer is a public health problem worldwide and Latin America (LATAM) cannot escape this reality. This malignant disease has not only a high prevalence in the region, but is also the main cause of cancer related deaths, and in other emerging countries, the incidence rates are still on the rise. Interestingly in most LATAM countries, lung cancer mortality has been decreasing in men but not in women, reflecting smoking patterns in countries such as Chile, Bolivia, and Brazil. Despite the fact that these issues are well known to government agencies, physicians and patients in the region, current efforts still fall behind those needed in order to face this problem of epidemic proportions. Tobacco control and smoking cessation are the most important interventions against lung cancer, but even with their optimal implementation (which is far from reality at this time) the number of cases in the foreseeable future would still be significant. Beyond tobacco control, advances in our understanding of the molecular component of lung cancer have resulted in new targeted therapies and immune check point inhibitors, which have improved clinical outcomes but at a considerably higher financial cost. LATAM has not widely and speedily adopted these strategies, including new technology and approved novel drugs, due to a number of facts, and therefore only a dismal proportion of LATAḾs patient population have benefited from these new advances. A keen focus on a heterogeneous education system for caregivers in lung cancer treatment would likely help standardize care and improve future potential gains from domestic research. In this review we discuss the challenges of treatment implementation, focusing on new technologies.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2018-05ORIGINALRaez, Luis E..pdfRaez, Luis E..pdfapplication/pdf221772http://18.204.144.38/bitstreams/32d4e82d-357c-44ed-ad85-83205fc9ab68/download3db98ea3ccf8ff15f31f727e9f67348dMD53LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/34ced02b-a2e8-4b4a-8098-fb1633e4b461/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILRaez, Luis E..pdf.jpgRaez, Luis E..pdf.jpgIM Thumbnailimage/jpeg11460http://18.204.144.38/bitstreams/2042d1a1-1ddb-4dd2-ae27-2bcf1b27de5c/downloadb70505959e6a479778e62b4a77bcf41cMD54TEXTRaez, Luis E..pdf.txtRaez, Luis E..pdf.txtExtracted texttext/plain66544http://18.204.144.38/bitstreams/a81a1a32-61ab-44bf-9c20-e6a2f22d6ecd/downloadf72e5479d74019bef6edc507541a2bb4MD5520.500.12495/3631oai:18.204.144.38:20.500.12495/36312024-02-06 22:24:33.704restrictedhttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.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